Targeting LIpid MEtabolism in Cancer and Neurodegenerative Diseases
At Lime, we are inventing breakthrough lipid-targeting therapeutics using our novel drug discovery platform.
Lime Therapeutics is a New York City-based Memorial Sloan Kettering Cancer Center spin-out utilizing a novel high-throughput screening approach for discovering lipid-targeting drugs for treating cancer and neurodegenerative diseases. Using our proprietary approach, we have identified and patented a lead drug candidate that increased mice lifespan in a metastatic non-small cell lung cancer model by 50%. This is the first drug in our planned pipeline of drugs targeting lipid metabolism. The time for lipid-altering therapeutics is now and we look forward to engaging with you to discuss how we are meeting this need.
Leadership
Scientific Advisory Board
Robert Schwartz, MD, PhD
Weill Cornell Medicine
Matthew
Vander Heiden, MD, PhD
Massachusetts Institute of Technology (MIT)
Rushika Perera, PhD
University of California,
San Francisco
Xuejun Jiang, PhD
Tuomas Tammela, MD, PhD
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Business Advisors
Avi Rosenbaum, PhD
Arthur Klausner, MBA
Life Sciences and Venture Capital Consultant
Advisors.bio
Parul Chachra, PhD, MBA
X (Google)
Technology
Creating Lipid-Altering Therapeutics
Cancers feed off nutrients, such as lipids (fats). In addition, excess lipid buildup is a hallmark of neurodegenerative disorders. Despite this, efforts to target lipid metabolism in cancer and neurodegenerative disorders have remained elusive due to lack of technology.
We've changed the game with the invention of an ultrasensitive lipid detection technology. LipidSense is a high-throughput screening platform that monitors lysosomal lipid flux in real time in live cells, in a well-plate format, and in live animals.
We can tell within seconds whether a particular therapy changes lipid flux. We are utilizing this platform to discover drugs that can alter cancer's access to lipids or restore lysosomal lipid function in neurodegenerative disorders.
The primary indication for our lead drug candidate is non-small cell lung cancer. We are also exploring therapeutic opportunities for this and other drugs in our pipeline for pancreatic, colorectal, and kidney cancer. Collectively, these four cancers represent a $50B total addressable market (TAM) and 462,000 patients diagnosed annually in the US.
Publications
A Carbon Nanotube Optical Reporter Maps Endolysosomal Lipid Flux.
Prakrit V. Jena, Daniel Roxbury, et. al.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707631/
An optical nanoreporter of endolysosomal lipid accumulation reveals enduring effects of diet on hepatic macrophages in vivo.
Thomas V. Galassi, Prakrit V. Jena, et. al.
News and Events
July 20, 2022
Meet the latest Harvard Business School Blavatnik Fellows: Dr. Shardule Shah
(Blavatnik Family Foundation)
June 15, 2022
Lime CEO, Dr. Shardule Shah, awarded Harvard Blavatnik Fellowship for Life Sciences Entrepreneurship (Harvard Business School)
March 30, 2022
Get to Know the 2022 NVC Business Track Finalists (Harvard Business School)
March 8, 2022
Lime Therapeutics selected as a 2022 Deerfield XSeed Award winner (Business Wire)
November 1, 2021
Lime Therapeutics wins Audience Choice Award at Pillar VC Pitch Competition
Our Supporters
Thank you to those supporting our efforts to develop life-changing therapeutics (partial list):
-BIOT.png)
Kent Johnson
Former CFO, BioLegend
Little Green Bamboo
Invest together. Grow together.
_edited.png)
If interested in pursuing an investment opportunity, please reach out.